CIPLA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,359 INR | -1.87% |
|
-2.94% | +9.03% |
| 09/05 | India's Alembic Pharma posts higher Q4 profit on strong N.America sales | RE |
| 08/05 | Indian Equities Settle Flat on Wednesday, Dragged by Banks, FMCG Stocks | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 258B 3.09B | Sales 2025 * | 280B 3.35B | Capitalization | 1,097B 13.15B |
|---|---|---|---|---|---|
| Net income 2024 * | 41.26B 495M | Net income 2025 * | 44.97B 539M | EV / Sales 2024 * | 4.04 x |
| Net cash position 2024 * | 55.83B 669M | Net cash position 2025 * | 82.44B 988M | EV / Sales 2025 * | 3.62 x |
| P/E ratio 2024 * |
26.6
x | P/E ratio 2025 * |
24.3
x | Employees | 32,323 |
| Yield 2024 * |
0.64% | Yield 2025 * |
0.68% | Free-Float | 64.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cipla Limited
More recommendations
More press releases
More news
| 1 day | -1.87% | ||
| 1 week | -2.94% | ||
| Current month | -2.94% | ||
| 1 month | -7.09% | ||
| 3 months | -4.32% | ||
| 6 months | +9.49% | ||
| Current year | +9.03% |
1 week
1 353.00
1 434.00
1 month
1 335.001 455.30
Current year
1 252.101 519.00
1 year
896.851 519.00
3 years
850.001 519.00
5 years
355.301 519.00
10 years
355.301 519.00
| Managers | Title | Age | Since |
|---|---|---|---|
Umang Vohra
CEO | Chief Executive Officer | 52 | 01/15/01 |
Ashish Adukia
DFI | Director of Finance/CFO | - | 16/22/16 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 01/86/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ashok K. Sinha
BRD | Director/Board Member | 72 | 16/13/16 |
| Chairman | 87 | 21/72/21 | |
| Director/Board Member | 83 | 16/77/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.99% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/24/09 | 1,359 | -1.87% | 1,152,636 |
| 08/24/08 | 1,385 | -0.18% | 1,497,782 |
| 07/24/07 | 1,387 | -2.54% | 1,085,239 |
| 06/24/06 | 1,423 | -0.09% | 929,301 |
| 03/24/03 | 1,425 | +0.33% | 804,513 |
Delayed Quote NSE India S.E., May 09, 2024 at 05:13 pm IST
More quotes
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Sector
Pharmaceuticals
Calendar
10/05/2024
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
1,359
INR
Average target price
1,453
INR
Spread / Average Target
+6.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.03% | 13.39B | |
| +18.67% | 43.74B | |
| +23.41% | 22.26B | |
| +16.41% | 14.9B | |
| +40.48% | 12.12B | |
| -8.84% | 6.92B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.13% | 5.47B | |
| +9.14% | 4.83B |
- Stock Market
- Equities
- CIPLA Stock